This site publishes clinical content about benfotiamine and the conditions it is applied to. Because the topic falls under Google’s “Your Money or Your Life” guidance, every claim is sourced, every page is dated, and every page is reviewed against the current literature.

Who writes and reviews

All clinical content on this site is authored or approved by Dr. Richard H. Mann, DPM — a board-certified podiatric physician and surgeon in active practice in Delray Beach, Florida. Dr. Mann is currently the sole reviewer; as the site grows, additional clinician reviewers will be named here with their credentials and the topics they cover.

Review cadence

Every long-form page — conditions, the benfotiamine hub, treatment protocols, and clinical updates — carries a visible last-reviewed date. Each page is re-reviewed at minimum every 12 months. Pages that are older than 12 months are flagged in our editorial dashboard and re-checked before any new traffic is sent to them.

What triggers an out-of-cycle review

A page is reviewed sooner than its scheduled cadence when any of the following happens:

• A new peer-reviewed study materially changes the evidence picture for a condition, mechanism, or dosing recommendation.
• The FDA issues new labeling, guidance, or a safety communication relevant to a treatment discussed on the page.
• A reader files a correction we judge to be accurate — we treat reader corrections as a serious editorial signal.
• A guideline body (AAN, ADA, AAOS, NIH) publishes an updated position statement on a condition we cover.

How to file a correction

If you find a factual error, a missing citation, or an outdated recommendation, please write to us using the contact formand select “Research / clinician.” Include the page URL, the specific claim in question, and a citation or source supporting the correction where possible. We aim to acknowledge corrections within five business days and to publish a fix — with the last-revieweddate updated — within fifteen.

Citations and conflicts of interest

Clinical claims link inline to the peer-reviewed literature that supports them, and our bibliographyaggregates those sources. Dr. Mann’s financial relationships — including his role as founder and CEO of Realm Labs, maker of NeuRemedy® — are disclosed in full on the disclosures page and flagged inline on every page that discusses a specific product or protocol.

What we do not publish

We do not publish sponsored content, content written by third parties without clinician review, or content generated by AI without a clinician’s edit and sign-off. Patient testimonials, when used, are marked as verified by Dr. Mann personally.